Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Abstract
References
SHEN Cun-si, YANG Fu-zhou, XIANG Ying-ying, CHEN Gu-yue, JI Jian-jian, ZHANG Zheng-guang. Study on the Synergistic Effect and Mechanism of Traditional Chinese Medicine Active Compound Galangin and Gefitinib on Non-Small Cell Lung Cancer[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(1): 72-76.
Citation: SHEN Cun-si, YANG Fu-zhou, XIANG Ying-ying, CHEN Gu-yue, JI Jian-jian, ZHANG Zheng-guang. Study on the Synergistic Effect and Mechanism of Traditional Chinese Medicine Active Compound Galangin and Gefitinib on Non-Small Cell Lung Cancer[J]. Journal of Nanjing University of traditional Chinese Medicine, 2021, 37(1): 72-76.
shu

Study on the Synergistic Effect and Mechanism of Traditional Chinese Medicine Active Compound Galangin and Gefitinib on Non-Small Cell Lung Cancer

  • 1.

    Jiangsu Key Laboratory of Pediatric Respiratory Disease, Institute of Pediatrics, Nanjing University of Chinese Medicine, Nanjing, 210023, China

  • 2.

    School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China

  • 3.

    School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China

More Information
  • Received Date: July 24, 2020
  • Available Online: December 20, 2021
  • Published Date: January 09, 2021
    Graphical Abstract
    • Abstract
  • OBJECTIVE   To explore the synergistic effect and possible molecular mechanism of TCM active compound Galangin and targeting drug Gefitinib on lung cancer.METHODS   The growth inhibition and apoptosis-promoting effect of Gefitinib and Galangin on A549 cells were detected by CCK-8 and flow cytometry, respectively. Western blot was used to detect the protein expression levels of apoptosis-related proteins and signal proteins in each groups.RESULTS   The combination for appropriate concentration of Galangin and Gefitinib more effectively inhibited the proliferation and promoted apoptosis of A549 cells, showing a good synergistic effect. The combination index (CI) measured by CompuSyn software less than 1. The results of Western blot showed that compared with Gefitinib alone, the combination of the two drugs further reduced the protein levels of p-EGFR, p-STAT3 and Bcl-2, and increased the protein levels of Cleaved Caspase-3, Cleaved PARP and Bax.CONCLUSION   In vitro, the combination of Galangin and Gefitinib have synergistic effects in the treatment of non-small cell lung cancer, and the inhibition of the proteins expression related to EGFR/STAT3 signal pathway may be one of the mechanisms, suggesting that the synergistic anticancer mode of the combination for the two drugs should be concerned.
    • FullText(HTML)
    • References (19)
  • [1]
    CAO M, CHEN W. Epidemiology of lung cancer in China[J]. Thorac Cancer, 2019, 10(1): 3-7. DOI: 10.1111/1759-7714.12916
    [2]
    XU CR, ZHONG WZ, ZHOU Q, et al. Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation[J]. Thorac Cancer, 2017, 8(1): 51-53. DOI: 10.1111/1759-7714.12382
    [3]
    张旭光, 尹航, 陈峰, 等. 高良姜素药理活性的研究进展[J]. 中国现代中药, 2016, 18(11): 1532-1536. https://www.cnki.com.cn/Article/CJFDTOTAL-YJXX201611029.htm
    [4]
    贺文煜, 张海明, 袁昌劲. 高良姜素通过PI3K/Akt及p38-MAPK信号通路增强胃癌SGC-7901细胞对阿帕替尼的敏感性[J]. 天津医药, 2019, 47(10): 1020-1025. DOI: 10.11958/20190272
    [5]
    YU S, GONG LS, LI NF, et al. Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways[J]. Biomed Pharmacother, 2018, 97: 213-224. DOI: 10.1016/j.biopha.2017.10.059
    [6]
    TOLOMEO M, GRIMAUDO S, DI CRISTINA A, et al. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells[J]. Cancer Lett, 2008, 265(2): 289-297. DOI: 10.1016/j.canlet.2008.02.025
    [7]
    CHOU TC. Drug combination studies and their synergy quantification using the Chou-Talalay method[J]. Cancer Res, 2010, 70(2): 440-446. DOI: 10.1158/0008-5472.CAN-09-1947
    [8]
    LU S, YU YF, YANG Y. Retrospect and prospect for lung cancer in China: Clinical advances of immune checkpoint inhibitors[J]. Oncol, 2019, 24(S1): S21-S30. http://www.onacademic.com/detail/journal_1000041676270999_1a05.html
    [9]
    LIN YT, CHEN JS, LIAO WY, et al. Clinicaloutcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations[J]. Int J Cancer, 2019, 144(11): 2887-2896. DOI: 10.1002/ijc.32025
    [10]
    YU S, GONG LS, LI NF, et al. Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-κB and Bcl-2/Bax signaling pathways[J]. Biomed Pharmacother, 2018, 97: 213-224. DOI: 10.1016/j.biopha.2017.10.059
    [11]
    LIU YN, ZHA WJ, MA Y, et al. Galangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma[J]. Sci Rep, 2015, 5: 11758. DOI: 10.1038/srep11758
    [12]
    LOH CY, ARYA A, NAEMA AF, et al. Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: Functions and therapeutic implication[J]. Front Oncol, 2019, 9: 48. DOI: 10.3389/fonc.2019.00048
    [13]
    ZHOU YJ, XIA LZ, LIU Q, et al. Induction of pro-inflammatory response via activated macrophage-mediated NF-κB and STAT3 pathways in gastric cancer cells[J]. Cell Physiol Biochem, 2018, 47(4): 1399-1410. DOI: 10.1159/000490829
    [14]
    LIU Y, WANG XH, ZENG S, et al. The natural polyphenol curcumin induces apoptosis by suppressing STAT3 signaling in esophageal squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 1-12. DOI: 10.1186/s13046-017-0664-4
    [15]
    LIU C, LIU H, WEN YZ, et al. Aspernolide A inhibits the proliferation of human laryngeal carcinoma cells through the mitochondrial apoptotic and STAT3 signaling pathways[J]. Molecules, 2019, 24(6): 1074. DOI: 10.3390/molecules24061074
    [16]
    ZHANG L, LU P, GUO X, et al. Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer[J]. Inflamm Res, 2019, 68(9): 751-760. DOI: 10.1007/s00011-019-01258-4
    [17]
    SEN M, JOYCE S, PANAHANDEH M, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer[J]. Clin Cancer Res, 2012, 18(18): 4986-4996. DOI: 10.1158/1078-0432.CCR-12-0792
    [18]
    HUYNH J, ETEMADI N, HOLLANDE F, et al. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies[J]. Semin Cancer Biol, 2017, 45: 13-22. DOI: 10.1016/j.semcancer.2017.06.001
    [19]
    JOHNSON DE, O'KEEFE RA, GRANDIS JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer[J]. Nat Rev Clin Oncol, 2018, 15(4): 234-248. DOI: 10.1038/nrclinonc.2018.8
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (628) PDF downloads (239) Cited by()
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return